Skip to main content
. 2022 Jun 17;20:3359–3371. doi: 10.1016/j.csbj.2022.06.016

Fig. 7.

Fig. 7

Further validation in a larger validation cohort, comprising 50 cases of HGSC and 50 unmatched cases with no current or previous history of cancer. Results of the pyrosequencing assay for OSR2 can consistently discriminate between normal FT and HGSC tissue across the first three methylated positions (A; P-value < 0.0001, t-test) and also with only the first methylated position (B; P-value < 0.0001, t-test). ROC analysis shows an AUC of 0.9573 (C; P-value < 0.0001).